Here’s a startling fact: infants hospitalized with respiratory syncytial virus (RSV) often fare far worse than those infected with SARS-CoV-2, the virus behind COVID-19. But why? A groundbreaking study published in Science Translational Medicine sheds light on this puzzling disparity, revealing that these two respiratory viruses trigger vastly different immune responses in young infants. And this is the part most people miss: understanding these differences could revolutionize how we treat these diseases.
During the COVID-19 pandemic, doctors noticed a curious trend: infants hospitalized with RSV typically exhibited more severe symptoms than those with SARS-CoV-2, despite both being respiratory RNA viruses. To unravel this mystery, researchers from St. Jude Children's Research Hospital and The Jackson Laboratory (JAX) compared the immune responses of infants hospitalized with either virus to those of healthy infants at a single-cell level. By analyzing proteins, genes, and epigenetic signatures in the blood, they uncovered the specific immune cells and signals driving these disparities.
But here’s where it gets controversial: the study found that severe RSV infections in infants were linked to surprisingly low levels of systemic inflammation and a poorly coordinated early immune response, primarily involving natural killer cells. This stands in stark contrast to the hyperinflammatory response seen in infants with SARS-CoV-2. Could this mean that RSV hijacks the immune system in ways we’ve yet to fully understand?
“What surprised us most was that the antiviral responses looked similar at first glance, but when we examined how immune genes were regulated, we saw striking differences,” said Dr. Duygu Ucar, a co-corresponding author from JAX. “RSV appears to reprogram parts of the infant immune system at the epigenetic level—essentially flipping molecular switches that control gene activity.” This raises a thought-provoking question: Could RSV’s ability to manipulate the immune system explain why it often leads to more severe outcomes?
To uncover these differences, the researchers analyzed blood samples from 19 infants with RSV, 30 with SARS-CoV-2, and 17 healthy infants, most around 2 months old. While both viruses triggered a similar rise in interferons (antiviral molecules), RSV-infected infants had significantly fewer natural killer cells and lower levels of interferon-gamma, a critical defense molecule. This finding was strongly linked to disease severity.
And this is the part most people miss: the study also highlighted that RSV suppresses key inflammatory signals like IL-1B and NF-κB, which typically help fight infections. In contrast, SARS-CoV-2 triggers a significant increase in pro-inflammatory molecules like TNF alpha. This distinction explains why anti-inflammatory treatments like steroids help some COVID-19 patients but may worsen RSV outcomes.
“One practical takeaway is that we should avoid routinely giving steroids to infants with RSV,” noted Dr. Asunción Mejías from St. Jude. “RSV already suppresses immunity, so adding steroids could further weaken the natural killer cell response.”
RSV remains the leading cause of infant hospitalizations and the second-leading cause of infant mortality worldwide. This study not only provides a blueprint for understanding infant immunity but also raises a critical question: How can we leverage these findings to develop better treatments for RSV and other early-life infections?
What do you think? Is RSV’s ability to reprogram the immune system the key to its severity? Or is there more to the story? Share your thoughts in the comments below!
